Activation of neurotensin receptor type 1 attenuates locomotor activity

Chelsea A. Vadnie, David J. Hinton, Sun Choi, Yubin Choi, Christina L. Ruby, Alfredo Oliveros, Miguel L. Prieto, Jun Hyun Park, Doo Sup Choi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Intracerebroventricular administration of neurotensin (NT) suppresses locomotor activity. However, the brain regions that mediate the locomotor depressant effect of NT and receptor subtype-specific mechanisms involved are unclear. Using a brain-penetrating, selective NT receptor type 1 (NTS1) agonist PD149163, we investigated the effect of systemic and brain region-specific NTS1 activation on locomotor activity. Systemic administration of PD149163 attenuated the locomotor activity of C57BL/6J mice both in a novel environment and in their homecage. However, mice developed tolerance to the hypolocomotor effect of PD149163 (0.1 mg/kg, i.p.). Since NTS1 is known to modulate dopaminergic signaling, we examined whether PD149163 blocks dopamine receptor-mediated hyperactivity. Pretreatment with PD149163 (0.1 or 0.05 mg/kg, i.p.) inhibited D2R agonist bromocriptine (8 mg/kg, i.p.)-mediated hyperactivity. D1R agonist SKF-81297 (8 mg/kg, i.p.)-induced hyperlocomotion was only inhibited by 0.1 mg/kg of PD149163. Since the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC) have been implicated in the behavioral effects of NT, we examined whether microinjection of PD149163 into these regions reduces locomotion. Microinjection of PD149163 (2 pmol) into the NAc, but not the mPFC suppressed locomotor activity. In summary, our results indicate that systemic and intra-NAc activation of NTS1 is sufficient to reduce locomotion and NTS1 activation inhibits D2R-mediated hyperactivity. Our study will be helpful to identify pharmacological factors and a possible therapeutic window for NTS1-targeted therapies for movement disorders.

Original languageEnglish (US)
Pages (from-to)482-492
Number of pages11
JournalNeuropharmacology
Volume85
DOIs
StatePublished - 2014

Fingerprint

Locomotion
Nucleus Accumbens
Neurotensin
Microinjections
Prefrontal Cortex
Brain
Neurotensin Receptors
Bromocriptine
Dopamine Receptors
Movement Disorders
Inbred C57BL Mouse
neurotensin type 1 receptor
Pharmacology
Therapeutics

Keywords

  • D2R
  • Locomotor activity
  • Neurotensin
  • NTS1
  • Nucleus accumbens
  • PD149163

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology
  • Medicine(all)

Cite this

Activation of neurotensin receptor type 1 attenuates locomotor activity. / Vadnie, Chelsea A.; Hinton, David J.; Choi, Sun; Choi, Yubin; Ruby, Christina L.; Oliveros, Alfredo; Prieto, Miguel L.; Park, Jun Hyun; Choi, Doo Sup.

In: Neuropharmacology, Vol. 85, 2014, p. 482-492.

Research output: Contribution to journalArticle

Vadnie, CA, Hinton, DJ, Choi, S, Choi, Y, Ruby, CL, Oliveros, A, Prieto, ML, Park, JH & Choi, DS 2014, 'Activation of neurotensin receptor type 1 attenuates locomotor activity', Neuropharmacology, vol. 85, pp. 482-492. https://doi.org/10.1016/j.neuropharm.2014.05.046
Vadnie, Chelsea A. ; Hinton, David J. ; Choi, Sun ; Choi, Yubin ; Ruby, Christina L. ; Oliveros, Alfredo ; Prieto, Miguel L. ; Park, Jun Hyun ; Choi, Doo Sup. / Activation of neurotensin receptor type 1 attenuates locomotor activity. In: Neuropharmacology. 2014 ; Vol. 85. pp. 482-492.
@article{0669871c233e434280bc256a8b9bd778,
title = "Activation of neurotensin receptor type 1 attenuates locomotor activity",
abstract = "Intracerebroventricular administration of neurotensin (NT) suppresses locomotor activity. However, the brain regions that mediate the locomotor depressant effect of NT and receptor subtype-specific mechanisms involved are unclear. Using a brain-penetrating, selective NT receptor type 1 (NTS1) agonist PD149163, we investigated the effect of systemic and brain region-specific NTS1 activation on locomotor activity. Systemic administration of PD149163 attenuated the locomotor activity of C57BL/6J mice both in a novel environment and in their homecage. However, mice developed tolerance to the hypolocomotor effect of PD149163 (0.1 mg/kg, i.p.). Since NTS1 is known to modulate dopaminergic signaling, we examined whether PD149163 blocks dopamine receptor-mediated hyperactivity. Pretreatment with PD149163 (0.1 or 0.05 mg/kg, i.p.) inhibited D2R agonist bromocriptine (8 mg/kg, i.p.)-mediated hyperactivity. D1R agonist SKF-81297 (8 mg/kg, i.p.)-induced hyperlocomotion was only inhibited by 0.1 mg/kg of PD149163. Since the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC) have been implicated in the behavioral effects of NT, we examined whether microinjection of PD149163 into these regions reduces locomotion. Microinjection of PD149163 (2 pmol) into the NAc, but not the mPFC suppressed locomotor activity. In summary, our results indicate that systemic and intra-NAc activation of NTS1 is sufficient to reduce locomotion and NTS1 activation inhibits D2R-mediated hyperactivity. Our study will be helpful to identify pharmacological factors and a possible therapeutic window for NTS1-targeted therapies for movement disorders.",
keywords = "D2R, Locomotor activity, Neurotensin, NTS1, Nucleus accumbens, PD149163",
author = "Vadnie, {Chelsea A.} and Hinton, {David J.} and Sun Choi and Yubin Choi and Ruby, {Christina L.} and Alfredo Oliveros and Prieto, {Miguel L.} and Park, {Jun Hyun} and Choi, {Doo Sup}",
year = "2014",
doi = "10.1016/j.neuropharm.2014.05.046",
language = "English (US)",
volume = "85",
pages = "482--492",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Activation of neurotensin receptor type 1 attenuates locomotor activity

AU - Vadnie, Chelsea A.

AU - Hinton, David J.

AU - Choi, Sun

AU - Choi, Yubin

AU - Ruby, Christina L.

AU - Oliveros, Alfredo

AU - Prieto, Miguel L.

AU - Park, Jun Hyun

AU - Choi, Doo Sup

PY - 2014

Y1 - 2014

N2 - Intracerebroventricular administration of neurotensin (NT) suppresses locomotor activity. However, the brain regions that mediate the locomotor depressant effect of NT and receptor subtype-specific mechanisms involved are unclear. Using a brain-penetrating, selective NT receptor type 1 (NTS1) agonist PD149163, we investigated the effect of systemic and brain region-specific NTS1 activation on locomotor activity. Systemic administration of PD149163 attenuated the locomotor activity of C57BL/6J mice both in a novel environment and in their homecage. However, mice developed tolerance to the hypolocomotor effect of PD149163 (0.1 mg/kg, i.p.). Since NTS1 is known to modulate dopaminergic signaling, we examined whether PD149163 blocks dopamine receptor-mediated hyperactivity. Pretreatment with PD149163 (0.1 or 0.05 mg/kg, i.p.) inhibited D2R agonist bromocriptine (8 mg/kg, i.p.)-mediated hyperactivity. D1R agonist SKF-81297 (8 mg/kg, i.p.)-induced hyperlocomotion was only inhibited by 0.1 mg/kg of PD149163. Since the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC) have been implicated in the behavioral effects of NT, we examined whether microinjection of PD149163 into these regions reduces locomotion. Microinjection of PD149163 (2 pmol) into the NAc, but not the mPFC suppressed locomotor activity. In summary, our results indicate that systemic and intra-NAc activation of NTS1 is sufficient to reduce locomotion and NTS1 activation inhibits D2R-mediated hyperactivity. Our study will be helpful to identify pharmacological factors and a possible therapeutic window for NTS1-targeted therapies for movement disorders.

AB - Intracerebroventricular administration of neurotensin (NT) suppresses locomotor activity. However, the brain regions that mediate the locomotor depressant effect of NT and receptor subtype-specific mechanisms involved are unclear. Using a brain-penetrating, selective NT receptor type 1 (NTS1) agonist PD149163, we investigated the effect of systemic and brain region-specific NTS1 activation on locomotor activity. Systemic administration of PD149163 attenuated the locomotor activity of C57BL/6J mice both in a novel environment and in their homecage. However, mice developed tolerance to the hypolocomotor effect of PD149163 (0.1 mg/kg, i.p.). Since NTS1 is known to modulate dopaminergic signaling, we examined whether PD149163 blocks dopamine receptor-mediated hyperactivity. Pretreatment with PD149163 (0.1 or 0.05 mg/kg, i.p.) inhibited D2R agonist bromocriptine (8 mg/kg, i.p.)-mediated hyperactivity. D1R agonist SKF-81297 (8 mg/kg, i.p.)-induced hyperlocomotion was only inhibited by 0.1 mg/kg of PD149163. Since the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC) have been implicated in the behavioral effects of NT, we examined whether microinjection of PD149163 into these regions reduces locomotion. Microinjection of PD149163 (2 pmol) into the NAc, but not the mPFC suppressed locomotor activity. In summary, our results indicate that systemic and intra-NAc activation of NTS1 is sufficient to reduce locomotion and NTS1 activation inhibits D2R-mediated hyperactivity. Our study will be helpful to identify pharmacological factors and a possible therapeutic window for NTS1-targeted therapies for movement disorders.

KW - D2R

KW - Locomotor activity

KW - Neurotensin

KW - NTS1

KW - Nucleus accumbens

KW - PD149163

UR - http://www.scopus.com/inward/record.url?scp=84903522296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903522296&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2014.05.046

DO - 10.1016/j.neuropharm.2014.05.046

M3 - Article

C2 - 24929110

AN - SCOPUS:84903522296

VL - 85

SP - 482

EP - 492

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -